Literature DB >> 2105091

Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-I.

G M Anantharamaiah1, Y V Venkatachalapathi, C G Brouillette, J P Segrest.   

Abstract

The major protein of high density lipoprotein (HDL), apolipoprotein (apo) A-I, is the major activator of the plasma enzyme lecithin:cholesterol acyltransferase (LCAT). A consensus amino acid sequence has been defined for the eight, 22-residue long, tandem amphipathic helical repeats located in the carboxy-terminal region of apo A-I. A series of 22 and 44mer synthetic peptide analogues of the consensus domain, differing only in their 13th amino acid residue, were prepared and tested for LCAT activation. One of the peptides was found to equal apo A-I in LCAT activation. This is the first time a peptide activator for LCAT that rivals the activity of apo A-I in the vesicular and discoidal egg phosphatidylcholine assay systems has been synthesized. Based on these results, we propose that the major LCAT-activating domain of apo A-I resides in the 22mer tandem repeats, each containing Glu at the 13th residue and located between residues 66 and 121 in the native apolipoprotein.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105091     DOI: 10.1161/01.atv.10.1.95

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  9 in total

Review 1.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

2.  Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.

Authors:  Maria V Fawaz; Sang Yeop Kim; Dan Li; Ran Ming; Ziyun Xia; Karl Olsen; Irina D Pogozheva; John J G Tesmer; Anna Schwendeman
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

3.  Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces.

Authors:  Nathan L Meyers; Libo Wang; Olga Gursky; Donald M Small
Journal:  J Lipid Res       Date:  2013-05-13       Impact factor: 5.922

4.  Dynamics of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I.

Authors:  Martin K Jones; Andrea Catte; Ling Li; Jere P Segrest
Journal:  Biochemistry       Date:  2009-12-01       Impact factor: 3.162

5.  Conformational analysis of apolipoprotein A-I and E-3 based on primary sequence and circular dichroism.

Authors:  R T Nolte; D Atkinson
Journal:  Biophys J       Date:  1992-11       Impact factor: 4.033

6.  Altered epitope expression of human interstitial fluid apolipoprotein A-I reduces its ability to activate lecithin cholesterol acyl transferase.

Authors:  L Wong; L K Curtiss; J Huang; C J Mann; B Maldonado; P S Roheim
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

7.  Nonsynonymous polymorphic sites in the apolipoprotein (apo) A-IV gene are associated with changes in the concentration of apo B- and apo A-I-containing lipoproteins in a normal population.

Authors:  A von Eckardstein; H Funke; M Schulte; M Erren; H Schulte; G Assmann
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

Review 8.  Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis.

Authors:  Luke J Leman; Bruce E Maryanoff; M Reza Ghadiri
Journal:  J Med Chem       Date:  2013-10-29       Impact factor: 7.446

9.  The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit.

Authors:  Belinda A Di Bartolo; Laura Z Vanags; Joanne Tm Tan; Shisan Bao; Kerry-Anne Rye; Philip J Barter; Christina A Bursill
Journal:  Lipids Health Dis       Date:  2011-11-30       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.